Molecular Partners leverages DARPins for oncology treatments, but Novartis' exit raises concerns. Click here to read why ...

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...

Additionally, they presented initial preclinical data for a second Radio-DARPin targeting mesothelin (MSLN), also co-developed with Orano Med, and further proof-of-concept data on a logic-gated ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...